Score IDs Patients With Upper Extremity DVT at Low Risk

This article originally appeared here.
Share this content:
Score IDs Patients With Upper Extremity DVT at Low Risk
Score IDs Patients With Upper Extremity DVT at Low Risk

FRIDAY, May 29, 2015 (HealthDay News) -- For patients with upper-extremity deep vein thrombosis (DVT), six easily available factors can be used to create a score that identifies those at low risk of adverse events during the first week, according to a study published online May 18 in the Journal of Thrombosis and Haemostasis.

Vladimir Rosa-Salazar, M.D., from the Hospital Clínico Universitario Virgen de la Arrixaca in Murcia, Spain, and colleagues used data from a registry to identify patients with upper-extremity DVT who were at risk for pulmonary embolism (PE), major bleeding, or death within the first week. The authors recruited 1,135 outpatients with upper-extremity DVT.

The researchers found that 0.26 percent of participants experienced PE, 0.18 percent had major bleeding, and 0.35 percent died during the first week. Patients were assigned points for chronic heart failure, creatinine clearance levels, recent bleeding, abnormal platelet count, recent immobility, and cancer. Sixty-seven percent of the patients scored ≤1 point and were classified as low risk. The rate of the composite outcome was 0.26 percent among low-risk patients, compared with 1.86 percent for other patients (C-statistic, 0.73).

"Using six easily available variables, we identified outpatients with upper-extremity DVT at low risk for adverse events within the first week," the authors write. "These data may help to safely treat more patients at home."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »